View Generic ICR - OIRA Conclusion



0910-0500 202008-0910-019
Historical Active 201706-0910-010
HHS/FDA Generic
Rapid Response Surveys
Extension without change of a currently approved collection   No
Regular
Approved without change 09/29/2020
Retrieve Notice of Action (NOA) 08/25/2020
Previous terms continue: This generic clearance for FDA is approved for 3 years under the following conditions: (1) For individual “surveys,” FDA shall submit a generic IC in ROCIS along with: (a) an abbreviated supporting statement in the template agreed to by OMB and FDA (including the problem being investigated, the method of selecting the sample, any deviations from the methods, procedures, or uses described in the overall supporting statement, and the estimated burden); (b) participant screeners; and (c) instruments/moderator guides. (2) OMB will respond with clearance or questions within 10 working days (or quicker if desk officer is alerted to an urgent public health need).
  Inventory as of this Action Requested Previously Approved
09/30/2023 36 Months From Approved 09/30/2020
60,000 0 60,000
30,000 0 30,000
0 0 0